DOUBLE CELLULAR ACTIVITY TO FIRM THE SKIN

v1

All these changes that occur inside the skin, result in a visible loss of

ELASTICITY and FIRMNESS over time.

At market level, there are many products designed to fight against

these signs of aging, orientated to a specific age group,

with different needs and reasons to buy anti-wrinkle treatment products.

Selective brands and their products are classified according to age:

+30, +40, +50, granting specific claims for each of them.

The target consumers for this product are those with mature skin, which

require an intense care beyond the anti-age treatments.

MARKET TRENDS

WHAT IS THE DERMO EPIDERMAL JUNCTION?

It is a basement membrane

responsible for the epidermis and

for the communication between

epidermal and dermal cells. DERMO EPIDERMAL JUNCTION (DEJ)

Basal laminaReticular lamina

Lamina lucida

Lamina

densa

This membrane is

composed by two

layers:

Collagen IV, Laminin, Perlecan

Collagen II/III

Epidermis

(cells)

Basement

membrane

Dermis

(Collagen)Laminin, Entactin

From the age of 30, the adhesion between epidermal and dermal cells

starts losing.

Certain features of the DEJ are altered by ageing process, such as:

WHY DOES OUR SKIN LOSE FIRMNESS?

Laminin-5 synthesis is decreased

in aged skin

The anchoring ability of

keratinocytes is altered by

Integrin expression deficiencies

•Both proteins, α6- Integrin and Laminin-5, form a cell structure called

Hemidesmosome.

•They are an anchoring point between keratinocytes and the Laminin-5 on

the basement membrane.

WHAT ARE THE HEMIDESMOSOMES?

OUR PRODUCT: Serilesine®

•Hexapeptide from an adhesion

sequence on Laminin, which

restores cutaneous structure.

•It is synthesized using solid phase

peptide synthesis (SPPS)

DESCRIPTION

SYNTHESIS

SERILESINE®

Laminin-5 production is boosted in fibroblasts

Laminin-5 synthesized by fibroblasts is essential for

the linking of keratinocytes to the basement

membrane

Treated

0.05 mg/mL SERILESINE®

Untreated

MOLECULAR EFFICACY - IN VITRO(I)

1. Stimulation of Laminin-5 production (I)

Laminin-5

Inmunofluorescence

•1st incubation: primary

monocolonal antibody

(recognises laminin-5).

•2nd incubation: secondary

polyclonal antibody (green

fluorescence) recognises

“Primary antibody +

Laminin-5”

Control

2. Stimulation of Laminin-5 production (II) were monitored in 3D Human

skin tissue models (*Red immunofluorescent stain for Laminin-5 in organotypic cultures)

+ 20% Synthesis of Laminin-5

IN-VITRO EFFICACY (II)

TreatedUntreated

SERILESINE® 0.005%

•EpidermFT full thickness

skin model

•Normal Human-derived

epidermal keratinocytes

(NHEK)

•Normal Human-derived

dermal fibroblasts (NHFB)

•Fluorescent quantification

by image analysis

Control

3. Stimulation of α6-integrin production (I) proved in human skin tissue

models. (*Green immunofluorescent stain for α6-Integrin)

Control

+ 75% Expression of Integrin-α6

UntreatedTreated•Evaluation by

immunohistochemistry

•Organotypic Cultures

•Fluorescence

quantification calculated

by image analisys

SERILESINE® 0.005%

IN-VITRO EFFICACY (III)

Green immunofluorescent stain

for α6-integrin in organotypic

cultures

Increase the number of Hemidesmosomes

4. Stimulation of Hemidesmosome formation, seen by transmission electron

microscopy (*The red arrows points out the hemidesmosomes)

Control Serilesine® Solution 10%

IN-VITRO EFFICACY(IV)

•Observation of hemidesmosomes

by transmission electron

microscopy as electro-dense

plaques.

TreatedUntreated

IN-VITRO EFFICACY(V)

4. Complementary Studies:

4.1 Specific keratinocytes adhesion:

Serilesine® is able to promote keratinocyte adhesion in a dose dependent manner.

4.2 Keratinocyte proliferation:

Serilesine® has shown a stimulatiry effect on keratinocyte cell growth of 38%.

4.3 Fibroblast proliferation:

Afer 48h, incubation with hexapeptide induced a 75% increase in fibroblast proliferation.

Histochemical study of human skin biopsies: this test is a replicate of the

in-vitro test, this time using a panel of volunteers.

1. Stimulation of Laminin-5 production (*Red Immunofluorescent stain

for Laminin-5))

0 months 2 months

EX-VIVO EFFICACY(I)

•3 volunteers

•Determination by

immunohistochemistry,

before and after two

month treatment.

•Cream containing 10%

Serilesine® Solution.

•Fluorescence

quantification was

calculated by image

analysis.

TreatedUntreated

+ 305% Synthesis of Laminin-5

2. Stimulation of α6-Integrin expression. (*Green immunofluorescent stain for α6-Integrin)

+ 405% Expression of Integrin-α6

TreatedUntreated

EX-VIVO EFFICACY (II)

0 months 2 months

1. Evaluation of skin appearance

+ 40% Skin compactness

+ 36% Skin tonicity

+ 45% Skin smoothness

IN-VIVO EFFICACY(I)

•20 Female volunteers, aged 18 to 70.

• A cream containing 10% Serilesine® Solution was applied twice a day during 60 days.

• Evaluation by a dermatologist.

Compactness

+40%

Tonicity

+36%

Smoothness

+45%

2. Evaluation of redensifying effect with10% Serilesine® Solution

• 20 Female volunteers, aged 55 to 64.

• The volunteers applied a placebo cream on one side of the

face and the cream containing 10% Serilesine® Solution on

the other, twice daily during 54 days.

Day 0 Day 54

+ 19% Increased cutaneous density

IN-VIVO EFFICACY (II)

Measurements were made

using the high frequency

echograph Dermascan C® 2D.

• 20 volunteers , aged 47 -65 years

• After 56 days a significant increase was observed: the cream containing

1% SERILESINE® had induced a long-term redensifying effect of 6%.

IN-VIVO EFFICACY (III)

3. Evaluation of the dermis density with 1% Serilesine® Solution

+ 6% redensifying effect

epidermis

dermis

epidermis

dermis

Day 0 Day 56

COSMETIC BENEFITS

Skin compactness

Double cellular activity

to firm the skin

Strenghthening of the dermo-

epidermal junction

Restructuring effectRedensifyingand improval

Increase the synthesis of:

• Laminin 5

•Integrin-α6

•Hemidesmosomes

Promotes a double-

cellular activity on

both keratinocytes

and fibroblasts

DESCRIPTION

Hexapeptide from an adhesion sequence of Laminin, which restores

cutaneous structure.

APPEARANCE

Aqueous solution containing 0.05% active ingredient.

INCI

Water (Aqua), Hexapeptide-10

FUNCTION

Redensifying and restructuring effect.

APPLICATIONS

Serilesine can be incorporated in cosmetic formulations such as emulsions,

gels, sera, etc., where restructuring and refirming of skin is desired.

DOSAGE

1-10%

TECHNICAL INFORMATION

DOUBLE CELLULAR ACTIVITY

TO FIRM THE SKIN

Disclaimer:

While the claims and supporting data provided in this publication are believed to be reliable and they are

presented free and for guidance only, there are no warranties of any kind. All expressed and implied

warranties are disclaimed. The recipient is solely responsible for ensuring that products marketed to

consumers comply with all relevant laws and regulations. LIPOTEC is the exclusive holder of the both

industrial and intellectual property rights identified herein. Recipient of this publication agrees to

indemnify and hold harmless each entity of the LIPOTEC organization for any and all regulatory action

arising from recipient’s use of any claims or information in this publication, including, but not limited to,

use in advertising and finished product label claims, and not present this publication as evidence of finished

product claim substantiation to any regulatory authority.

All tradenames, trademarks, copyrights and images used herein belong to their respective and lawful owners